References

22. Leary T (1934) Atherosclerosis, the important form of arteriosclerosis, a metabolic disease. JAMA, 105: 475–481.
184 References

120. Goldstein JL, Schrott HG, Hazzard WR, Bierman EL & Motulsky AG (1973) Hyperlipidaemia in coronary heart disease. II. Genetic analysis of lipid levels in 176


230. In 1964 Owren et al., reported in the Lancet (ii: 975–979) that linolenic acid, or linseed oil reduced platelet adhesiveness. This finding was subsequently retracted (Lancet 1965, ii: 849 and Ann Int Med 1965; 63: 1160–1161) and not confirmed by CF Borchgrevink et al. (Lancet 1965; ii: 980–982).


References


202 References


References


References 207

References


References


References


Index

A
“ABC of Nutrition”, 158
Abell-Kendall method for plasma cholesterol, 17–18
Abetalipoproteinaemia, 31
Adenosine A1/A2 receptors, 91
Adipose tissue fatty acid biopsy, 59–60, 101–102, 122
African Americans, 149–150
Aggregometer(s), 78
Ahrens, E. H., 14, 16, 98, 175
Albrink, M. J., 25
Alcohol, 30, 37, 43–44, 83–90, 145, 147
Alcoholism, 8, 83–84, 88, 111
Allbutt, Sir. C., 1, 140
Allen, F. M., 140
Alpha-lipoprotein (cholesterol), 10, 31, 41, 88
Alpha-tocopherol, 104–106
Alpha-tocopherol, beta-carotene prevention study, 101, 106
American Heart Association, 131, 136, 157–158, 176–177
Angina pectoris, 1–2, 4, 173
Anitschkow, N., 5–8, 129, 174
Antioxidants, 88–90, 103–107, 158–159, 178
Apo B-100 lipoprotein, 130
Apo E lipoprotein, 54
Arachidonic acid (20:4 ω-6), 78, 123
Arteriosclerosis, 2, 6
Aschoff, L., 5–7, 9
Aspirin, 71–73, 117
Atheroma, 5, 7, 9–10, 40, 49–50, 71, 83, 129, 135
Atherosclerosis, 5–11, 16, 42, 45, 50, 57, 70, 75, 83–84, 103–104, 117, 126, 129, 133, 141, 174
Atorvastatin, 116
“Atromid” (ICI), 62, 127
B
Baby foods, 150–151
Bang, H. O., 77–79
Battarbee, H. D., 151–152
Beard, T., 147–148
Bedford, D. E., 3–4, 173
Berlin wall (fall of), 170
Beta-carotene, 105–106
Beta-lipoprotein cholesterol, 10, 15, 26, 41
Beta-sitosterol, 125–128
Bile acids, 18, 53, 61–62, 64, 131, 174
Blackburn, H., v–vi, 35, 38, 74
Bloch, K., 119
Blood pressure
diastolic, 140, 142, 146, 149–150
systolic, 140, 142, 145–150
Body mass index (BMI), 66–70, 145, 148, 164
Boston Collaborative Drug Surveillance Program (BCDSP), 92
Breast milk, 139, 150
British Isles, 167–168
Bronte-Stewart, B., 14–15, 89, 98, 175
Brown, M. S., 18, 103, 118
Burr, M. L., 81
Butter, 13, 15–18, 59, 98, 100, 114, 128, 166, 173, 176
C
Cafestol, 94–95
Caffeine, 91–92, 94–96
Campesterol, 125–127
Canada, 77, 88, 92, 116, 161–164, 167
Cancer, 57, 59–60, 62, 86, 101, 105–107, 118, 176
Canola oil, 109, 114
Cape Town, 11, 14, 50
Cardiologists, 71–72, 90, 114, 175–176
Cardiovascular disease(s), 69, 81, 90, 106–107, 133–137, 140, 155
Case-control studies, 10, 22, 42–43, 69, 85, 93, 107, 122–123, 134, 174
Casein, 129–132
Cerebral arteries, 7
Chalatow, S., 6
Charnock, J. S., 80, 165
CHD mortality, 4, 35, 38–40, 46–47, 60, 66, 79–81, 85, 93, 112, 123, 149, 161–171, 173, 177
Cheyne, G., 2
Chimpanzees, 148–149
Cholesterol, 174
  absorption, 18, 53, 127
  biosynthesis, 18, 54, 61, 119
  pools, 42, 69
  radiolabelled, 42
Cholesteryamine, 62, 113–118
Chylomicrons, 25, 29, 31, 42
Cirrhosis (liver), 83–84, 86, 90
Cis unsaturated fatty acids, 14, 18–19, 36, 47, 97–99, 101
Clofibrate, 62, 116
Coagulation tests (in vitro), 50
Cochrane, A (on wine), 85, 89
Coffee, 91–96, 135, 159
  different methods of preparing drink, 95
Cohort(s), 21–22, 24, 34–36, 38, 66, 70, 72, 79, 84–85, 87–89, 92–93, 101, 104–105, 107, 121–123, 134, 149, 155, 166, 175
COMA, Committee on Medical Aspects of Food Policy (UK), 40, 56, 81, 157
Connor, W. E., 16, 52, 127
Constantinides, P., 45, 71
Coronary angiography, 71–72, 113–114
Coronary artery ligation, 2–3
Coronary artery narrowing, 1
Coronary Drug Project, 61–62
Coronary thrombosis, 1–4, 173
Cretel, 34, 36–37
Cross sectional studies, 51, 53
  “Cytellin” (Eli Lily), 126–127

D
Dahl, L., 141–144, 146–148, 150, 152–154
Dahl’s line, 142–143, 147–148
Darby, B., 151
DART trial, 81, 111
DASH trials, 107, 158
Dawber, T. R., 21–22
Decline in CHD mortality, 162–164, 167
De Langen, C. D., 16–17
De la Salle P., 174
Denmark, 77–78, 116
Denton, D., 148
Desirable weights (for height)
  original, 67
  revised, 152
Diabetes (mellitus), 67, 70
Dietary cholesterol, 13–14, 51–56, 119, 158
Dietary fat-cholesterol hypothesis, 38
Dietary fibre, 63
  insoluble, 64
  viscous, soluble, 64
Dietary Goals for the US (1977), 139, 151–152
Dietary and Nutritional Survey of British Adults, 147
Dietary prescriptions, 158
Dietary trials for prevention of CHD, 57, 60, 109, 118
Dietschy, J. M., 19, 53
Dihomo-γ-linolenic acid, 78
Doll, Sir. R., 21–23, 86, 88, 105
D-Thyroxine, 61
Duguid, J. B., 50
Dwyer, T., 165, 167
Dyerberg, J., 77–79
Dyslipidaemia, 70

E
East European countries, 169–171
EFA (essential fatty acid) deficiency, 17
Egg yolk, 6, 52, 54, 129, 158
Eicosanoids, 78
Eicosapentaenoic acid (EPA), 78–79, 124
Einhoven, W., 2, 173
Elaidic acid, 99–100
Electrocardiogram, 1–3, 35, 173
Endo, A., 119
Epstein, F. H., viii, 23, 68, 171
Esksimo(e)s, 77–79, 142–143
Essential hypertension, 139–140, 142–144, 151, 154
EURAMIC study, 101
Euratom Study, 37
European Atherosclerosis Society’s Study Group, 75
Exercise, 27, 44, 47, 57, 112–113, 135, 155, 178

F
Factor VII (coagulation), 50, 72, 73
Faecal bile acids, 18, 61, 64
Faecal neutral steroids, 53
Familial combined hypercholesterolaemia, 31, 62, 127–128
Familial hypercholesterolaemia, 10, 31, 92, 127–128
FAO/WHO Joint Expert Consultation on Fats & Oils in Human Nutrition, 123
Fat
consumption, 23, 39, 171, 173–174
dietary, 10, 14–18, 38, 46–47, 51, 73, 109–111, 121–122, 126, 174–175, 178
Fatty fish, 79, 81, 111, 159, 177
Ferro-Luzzi, A., 37
Fibre, see Dietary fibre
Fibrin, 50, 72
Fibrinogen, plasma, 50, 72–73, 89
Fibrinolysis, 50, 72
First World War, 2
Fish oil(s), 77–81, 100, 105, 123–124, 168
Flavonoids, 64, 89, 96, 107, 159
“Flora” margarine (Unilever), 128
Fluvastatin, 116
Folic acid and folate, 64, 90, 107, 135–137
Food & Drug Administration (US), 116
Frame
large, 66
medium, 66
small, 66
Framingham, Mass, 21–24, 27, 46, 67–68, 70, 75, 85, 92–93, 134–135, 175
Frederickson, D., 29–31
French paradox, 89–90
Fruit and vegetables, see Vegetables and fruits

G
Gabon, 146, 148
Gallstones, 17, 62, 174
Gas (liquid) chromatography, 14, 17, 95, 98, 100–102, 121, 127, 175
Gemfibrozil, 116–119
GISSI (Gruppo Italiano per lo Studio della Sopravivenza Infarto Miocardico), 81, 105
Gofman, J. W., 10, 43, 174
Goldstein, J. L., 18, 31, 103, 118
Gordon, T., 23, 42, 46, 162
Gothenburg, 69
Greenland, 77–79, 142
Groen, J., 14, 175
Guyton, A. C., 153

H
Haemostatic effects, 88–89
Harrison’s textbook of Medicine, 27, 74
Hautvast, J. G. A. J., 43
Hawaii, 23, 87–88, 92
HDL$_2$ and HDL$_3$, 43, 88–89
HDL-cholesterol, plasma, 10, 27, 41–44, 69, 75, 88–89, 99–100, 116
HDL in serum methods, 134–135
Hegsted, D. M., 17, 52, 54
Helsinki Heart Study, 116
Helsinki mental hospitals trial, 111
Herrick, J. B., 2–3, 71
Hetzel, B (Dwyer & Hetzel), 165, 167
HMG CoA reductase, 54, 119
Homocysteine, plasma, 133–137
Homocysteine, plasma total, tHcy, 134–135
Homocystinuria, 133–135
Hornstra, G., 73
Hulley, S. B., 26
Hunter-gatherers, 11, 106
Hydrogenated vegetable fat/oil, 15, 101
Hyper and hypo-responders to dietary cholesterol, 54
Hyperlipoproteinemia
Type I, 30
Type II, 30, 115, 130
Type IIa, 30
Type IIb, 30
Type III, 30
Type IV, 30
Type V, 30
Hypertension, 10, 14, 38, 47, 64, 66, 67, 70, 139–155, 164–167, 174–175, 177
Hypertriglyceridaemia, 31, 72–73

I
Ignatowski, A. I., 5, 129
Immunofluorescent staining, 50
Individual responsiveness to cholesterol intake, 54
Institute of Medicine (USA), 155
International Classification of Diseases, 4, 161–162, 173
Intersalt Study, 145, 148
Intra-abdominal fat, 69
Inuit, 77
Iodine value, 14, 59, 98
Ischaemic heart disease, 105, 146
Isoflavones, 131–132
Index

J

K
Kahweol, 94–95
Kaiser-Permanente Health Plan, 84
Katan, M., 54, 91, 94–95, 99, 167, 169
Kempner, W., 14, 141, 174–175
Keys, A., 11, 13, 18, 33, 84, 141, 174
Keys’ equation, 16–17, 55
Kidneys, and sodium excretion, 142, 144–148, 153–155
Kinsell, L. W., 14, 52, 175
Klatsky, A. L., 84, 87
Korotkoff, N. S., 140
Kritchevsky, D., 10, 45
Kromhout, D., 36, 38, 79
Kung bushmen, 11, 146
Kwashiorkor, 63, 130

L
LDL receptor in cell membranes, 18–19, 103
Leaf, A., 80–81, 96
Leary, T., 8
Life insurance companies, 35, 65, 68, 92
Life-years, 86
Linoleic acid (18:2 ω-6), 121, 124, 158
Linolenic acid (18:3 ω-3), 79, 124
Lipid infiltration (of arterial wall), 49–50
Lipid Research Clinics, 88, 93, 115, 130
Lipoprotein(s), plasma, 31, 42
Los Angeles (VA) Trial, 58–60, 68
Lovastatin (mevinolin), 116–119
Lynen, F., 119
Lyon(s) Diet Heart Study, 114

M
MacGregor, G. A., 145, 146
Macrophages, 6, 103
Madrid, 11
Mann, G. V., 45–47
Mann, J. I., 46
Marchand, F., 5
Margarine
hard, 173
soft (tub), 59, 176
Marmosets, 80
Masai, 47
“Maxepa” capsules, 81
McCully, K. S., 133
McGill, H. C., 53–54
McLennan, P. L., 80, 114, 165
McMichael, Sir. J., 45–46
Meade, T. W., 72, 73, 89
Mediterranean
Countries, 174
Diets, 36–37, 106–107, 114
Meneely, G. R., 151–152
Merskey, C., 50
Meta-analysis, 55, 93, 118, 145, 149, 175
Metropolitan Life Insurance Company tables, 66
Mevalonate, 119
Miettinnen, M., 60, 122, 128
Miller, G. J., 42, 88
Miller, N. E., 42–43, 88
Minnesota code for ECGs, 35
Minnesota, University of, 11, 35
MONICA (WHO) project, 69, 90
Monkeys, 131
Monounsaturated fatty acid(s), 80, 98–99, 158
MRFIT, Multiple Risk Factor Intervention Trial, 112
MTHFR mutation (5,10 methylenetetrahydrofolate reductase), 135
Mural thrombi, 50
Myristic acid (14:0), 17

N
Na+, K+-ATPase, 154
Naples, 11, 131
National Cholesterol Education Program (US), 75
National Heart Institute (US), 22, 29
Neomycin, 61
Nestel, P. J., 53, 69
New Zealand, 75, 86, 92, 116–117, 142, 164–167, 171
NHANES, 93, 149
Nicotinic acid, 61, 118, 127
NIH Consensus Development Conference 1984/575
Nordic countries, 166–167
North Karelia, 38, 166
Northwick Park Heart Study, 72–73
Nurses cohort (US/Harvard), 92, 101, 104–105, 122

O
Oatmeal, 64, 159
Obesity, 65–70
Obrastzow, W. P., 2
Oestrogens, 43, 58, 61, 131
Oleic acid (18:1), 99
Olive oil, 14–16, 37, 80, 98, 114
Oliver, M. F., 10, 41, 118, 123
Osler, Sir. W., 1, 139
Oslo trial, 58
Ouabain, endogenous, 154
Overweight, 35, 65–68, 70, 111, 113, 149, 152, 158, 171, 176, 178
Oxidised LDL hypothesis, 103–104

P
Page, L. B., 147
Palmitic acid (16:0), 99
Paper electrophoresis, 10, 29, 41, 174
Parkinson, J., 3–4
PCSK9 gene, 118
Pectin, 64, 159
Phytoestrogens, 131
Pickering, Sir. G., 49, 144
Plant sterols/phytosterols, 18, 125–128
Plaque, atheromatous, 5, 7, 7, 49–50, 71, 135
Platelet aggregation, 58, 73, 78–80, 85, 123
Platelets, 50, 72–73, 78–79
Poland, 113, 169–171
Polyphenols, 89
Polyunsaturated fatty acid(s) (PUFA), 17, 36, 38, 60, 78, 80, 98–99, 103, 106, 126, 158
Ponderal index, 68
(The) Pooling Project, 67
Potassium (K), 95, 107, 144–145, 148, 151–152
Pravastatin, 116–117, 119
Pregnancy, 43, 146
“Present Knowledge in Nutrition”, 56, 151
Primary prevention trials, 46, 58, 111
Prospective (cohort) studies, 21–22, 24, 70, 72, 79, 87, 89, 93, 101–102, 104–105, 107, 121–123, 134, 149, 175
Prostacyclin (PGI₂), 78

Q
Quetelet, L. A. J., 67

R
Rabbits, 5–8, 45–46, 50–53, 80, 103–104, 129–131, 133, 174
Randomised controlled trials of dietary fat: effect on CHD, 110
Rats, 80
salt-resistant, 153–154
salt-sensitive (Dahl), 139, 153–154
Regression of atherosclerosis, 7, 40
Relative weight, 35, 67–68
Reperfusion (of the heart), 71–72, 80
Retrospective studies, 21, 175
Rockefeller University (Hospital), 18, 52, 55
Rose, G., 40, 167
Royal College of Physicians Report (1976), 39, 176–177
Russia, 5–6, 140, 170

S
Salt (NaCl), 139–153, 155
discretionary, 152
in processed food, 151–152
Saturated fatty acid(s), 13–15, 17–19, 36, 38, 47, 56, 60, 72–73, 77–78, 98, 102, 114, 123, 157–158
Schoenheimer, R., 9, 125
Schweitzer, A., 146
Scientific Advisory Committee on Nutrition (British), 155
Serum triglycerides, 24–27, 39, 62, 69
Seven Countries Study (7CS), 33–38, 68, 173, 175
Sf 10–20 lipoproteins, 10, 174
Shaper, A. G., 85, 86
Shekelle, R. B., 23, 79, 122
Simvastatin, 116–117, 119
Sinclair, H. M., 11, 17, 77, 79
Sirtori, C. R., 129–131
Sitostanol, 125, 127–128
Sitosterolaemia (phytosterolaemia), 127
Skinfolds, 35, 68–69
Smith, F. M., 2–3
Society of Actuaries Build and Blood Pressure Study, 66
Sodium (Na)
intracellular, 153–154
low sodium diet, 141, 144, 151–152
renal (urinary) sodium excretion, 142, 146, 154
salt intake–discretionary, 152
sodium/potassium ratio, 144, 151
total exchangeable sodium, 143
Solomon Islands, 147
South Africa, 33
Southern Europe, 169
Soya bean oil trial, 58, 60
Soy protein(s), 129–132, 178
Species differences in cholesterol metabolism, 53
Sphygmomanometer, 140
Square root of cholesterol intake, 17, 51–52, 55
Stamler, J., 40
Statins, 47, 75, 115–119, 127–128, 164, 171, 175, 177
Stearic acid (18:0), 17, 99–100, 168
Steinberg, D., 103–104, 175–176
Sterol balances, 18, 52–53
St. Petersburg, 5–8, 140
Straschesko, N. D., 2
Stroke, 22, 69, 133–134, 146
Stuckey, N. W., 5–6, 129
Sucrose/sugar, 36–37, 39–40, 58, 92, 126, 130, 141, 157, 173, 176
Sudan III, 6–7
Sunflower seed oil, 6, 15–16, 80, 123
Sweden, 16, 25, 88, 116, 167, 169
T
Tall oil, 127
Tangier disease, 31, 42
Tea, 91–92, 94–96
Tecumseh, 23, 46, 67–68
Thelle, D., 93
Thiazides, 144–145
Thrombogenic hypothesis, 50
Thrombolysis/thrombolytic treatment, 72
Thrombosis, 1–4, 46, 49–50, 71–75, 88, 121, 123, 134–135, 164, 173, 177
Thromboxane A2, 71, 73, 78–79, 123, 135
Time magazine, 150, 177
Trans (unsaturated) fatty acids, 158
industrial, 97, 99–101
in ruminants and dairy food, 97, 100–101
Trial(s): diet and CHD outcome, 4, 40, 45, 57–60, 179
Trials: diet and serum cholesterol, 16, 57–62
Trial(s): drugs and CHD outcome, 61–62, 92, 115–119, 171
Triglycerides
dietary, 30, 51
plasma, 25, 29, 39–40, 71, 79–80, 124, 158
Triparanol, 61
Trowell, H., 63
U
Ultracentrifuge, 10–11, 24, 43, 174
V
Vaccenic acid, 97, 100
Vegetables and fruit, 63–64, 89, 106–107, 159
Ventricular arrhythmia, 80
Ventricular fibrillation, 77, 80–81, 170
Virchow, R., 50
Visceral adiposity, 69, 158
Vitamin B-6, 133, 135
Vitamin B-12, 133, 135–137
Vitamin C, 77, 107
Vitamin E, 81, 103–106
Vitamins, 15, 77, 81, 104–107, 133, 135–137, 141, 174
VLDL (very low density lipoproteins), 25, 31, 42, 75
Western Electric Study (Chicago), 23, 67, 79, 93, 122
Western Europe, 168–169
Wheat fibre, 63–64
White, P., 10
WHO Collaborative Trial & Multifactorial Prevention of CHD, 109, 112
Wageningen University (Netherlands), 43, 94
Waist circumference, 65, 69
Weight reduction, 44, 67, 157–158
Wheat fibre, 63–64
WHO Collaborative Trial & Multifactorial Prevention of CHD, 109, 112
Index

WHO Expert Committee (1982), 46–47, 74, 176–177
Whole grain cereals, 63–64
Wilcken, D., 133
Wilcken, B., 133
Willett, W., 170
Windaus, A., 5–6, 9
Wine, 85, 87–89
   red wine, 83, 89
Wood, P., 10
World War, 2, 35–36, 173

X
Xanthomas, 127
   tendon xanthomas, 127
Xanthomatosis, 45, 174

Y
Yanomamo tribe (Amazon), 146, 148
Yudkin, J., 39–40, 45

Z
Zutphen cohorts (Netherlands), 34, 36, 79